Back

Effect of concomitant antiplatelet agents on clinical outcomes in the Edoxaban versus Warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial

25 August 2018 (11:00 - 16:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Atrial fibrillation - Stroke Prevention Cardioversion and Defibrillation ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Andreas Goette

Saint Vincenz Hospital Paderborn, Paderborn (Germany)

8 More presentations in this session

Presentation thumbnail
Doctor S. Camen (Hamburg, DE)
Abstract
Presentation thumbnail
Doctor M. Anguita Sanchez (Cordoba, ES)
Abstract
Presentation thumbnail
Doctor M. Cho (Seoul, KR)
Abstract
Presentation thumbnail
Doctor Y. Koretsune (Osaka, JP)
Abstract Slides
Presentation thumbnail
Doctor Y. Yao (Beijing, CN)

Access the full session

Session thumbnail
Poster Session 1 - Atrial fibrillation - Stroke Prevention

The Event

Event poster

ESC Congress 2018

25 August 2018 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Edoxaban treatment in real-world practice is highly concordant with ESC atrial fibrillation guidelines: results from the non-interventional global ETNA-AF program
27 August 2021
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
19 July 2023
thumbnail
Congress Presentation
Left atrial thrombus in heart failure patients undergoing elective electrical cardioversion despite guideline-recommended anticoagulation: prevalence, predictors and prognosis
12 April 2026
thumbnail
Congress Presentation
Direct oral anticoagulants vs warfarin in non-valvular atrial fibrillation. Meta-analysis, includes all published trials.
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources